Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
0.3910
-0.0174 (-4.26%)
Mar 31, 2025, 2:29 PM EDT - Market open
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,525,776
Market Cap
8.62M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4 | 0 | - |
Dec 31, 2023 | 4 | 0 | - |
Dec 31, 2022 | 4 | 1 | 33.33% |
Dec 31, 2021 | 3 | 0 | - |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ACXP News
- 13 days ago - Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - PRNewsWire
- 20 days ago - Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering - PRNewsWire
- 24 days ago - Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering - PRNewsWire
- 4 weeks ago - Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics - PRNewsWire
- 4 weeks ago - Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update - PRNewsWire
- 5 weeks ago - Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI - PRNewsWire
- 5 weeks ago - JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors - PRNewsWire